Fundz

Orvida Pharma secures interim financing led by Recordati to advance ontivatrep development for rare genetic skin diseases.

PRIVATESep 15, 2026

Round Type

Venture

Center DistrictBiotechnologyHealth CareTherapeuticsPharmaceuticalBiopharma

Investors

Recordati

Description

Orvida Pharma has announced the completion of an interim financing led by Recordati. This financing will support the continued clinical development of ontivatrep, an oral TRPV3 inhibitor. Additional resources will also aim to advance Orvida’s broader pipeline of programs targeting rare genetic skin diseases. The involvement of Recordati strengthens Orvida's ability to reach important clinical milestones.

Who else raised in Therapeutics and Pharmaceutical around the same time

Companies in the same sectors as Orvida Pharma that raised within 45 days of this round, from Fundz verified event records.

  • Quanta Therapeutics raised an undisclosed amount (Series D) on October 24, 2026.
  • Disc raised $422M (Post-IPO Equity) on October 20, 2026.
  • Os Therapies raised $7.2M on October 15, 2026.
  • Acta Pharmaceuticals raised $24M (Seed) on October 15, 2026.
  • Ensho Therapeutics raised $7.3M on October 2, 2026.
  • Breye Therapeutics raised $77M (Series A) on September 29, 2026.

Who to call at Orvida Pharma, and when

A new round usually means Orvida Pharma is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day Orvida Pharma raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Orvida Pharma, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Orvida Pharma. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Orvida Pharma

Location

Center District, Israel

About

Orvida Pharma is a clinical-stage biotechnology company developing first- and best-in-class treatments for rare and severe genetic skin diseases. Their lead investigational candidate, ontivatrep, is a novel, highly specific, and selective oral TRPV3 inhibitor being developed for the treatment of Olmsted syndrome, severe keratodermas, and ichthyosis. The management team comprises industry leaders with deep expertise in drug discovery, dermatological pharmaceutical development, and rare disease therapeutics.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Orvida Pharma raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

1 contact
Verified contactsLiora, Chief Scientific Officer hiddenSee plans and pricing
Predictive Intelligence
Strategic

ML-powered predictions for Orvida Pharma's next move

See what Strategic adds

Orvida Pharma raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.